Search results
Novartis (NVS) Stock Slides as Market Rises: Facts to Know Before You Trade
Zacks via Yahoo Finance· 4 months agoIn the latest market close, Novartis (NVS) reached $108.03, with a -0.21% movement compared to the...
Novartis (NVS) Stock Dips While Market Gains: Key Facts
Zacks via Yahoo Finance· 2 months agoNovartis (NVS) closed the latest trading day at $99.77, indicating a -1.58% change from the previous...
Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Investor's Business Daily· 1 month agoBiotech stocks heated up Thursday, driven by a spate of deals, as Novartis scooped up a licensing...
Novartis (NVS) Stock Sinks As Market Gains: Here's Why
Zacks via Yahoo Finance· 5 months agoThe latest trading session saw Novartis (NVS) ending at $98.87, denoting a -0.84% adjustment from...
Novartis (NVS) Stock Moves 0.22%: What You Should Know
Zacks via Yahoo Finance· 4 months agoIn the latest market close, Novartis (NVS) reached $108.47, with a +0.22% movement compared to the...
Novartis (NVS) Increases Yet Falls Behind Market: What Investors Need to Know
Zacks via Yahoo Finance· 2 months agoNovartis (NVS) closed at $95.88 in the latest trading session, marking a +0.64% move from the prior...
Novartis (NVS) Chronic Myeloid Leukemia Drug Approved by EC
Zacks via Yahoo Finance· 2 years agoNovartis NVS announced that the European Commission (EC) has approved Scemblix (asciminib) for the...
Investors Heavily Search Novartis AG (NVS): Here is What You Need to Know
Zacks via Yahoo Finance· 2 months agoZacks.com users have recently been watching Novartis (NVS) quite a bit. Thus, it is worth knowing...
Novartis (NVS) Increases Despite Market Slip: Here's What You Need to Know
Zacks via Yahoo Finance· 4 months agoNovartis (NVS) closed the latest trading day at $101, indicating a +0.03% change from the previous...
Could This Medicine Be the Next Winner for Novartis?
Motley Fool· 9 months agoEarlier this month, the Switzerland-based pharmaceutical Novartis (NYSE: NVS) shared encouraging news from two phase 3 clinical trials of its drug...